Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | p53-SLP vaccine |
Synonyms | |
Therapy Description |
A vaccine consisting of synthetic peptides derived from the middle part of p53 used to stimulate the host immune system to mount a cytotoxic T-cell lymphocyte response against p53-expressing tumor cells (PMID: 26334096). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
p53-SLP vaccine | p53 Vaccine 5 | A vaccine consisting of synthetic peptides derived from the middle part of p53 used to stimulate the host immune system to mount a cytotoxic T-cell lymphocyte response against p53-expressing tumor cells (PMID: 26334096). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
TP53 wild-type | ovarian cancer | no benefit | p53-SLP vaccine | Phase II | Actionable | In a Phase II trial, p53-SLP vaccine was demonstrated to be safe, well tolerated and to induce p53-specific T-cell responses in ovarian cancer patients; however clinical impact was lacking (PMID: 19621448, PMID: 21328579). | 21328579 19621448 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|